Frankfurt (15 December 2020) – Today, MV Index Solutions GmbH (MVIS®) announced the licensing of the BlueStar Genomic Health Care Index (ticker: BDNANTR) to Migdal Mutual Funds,a leading Israeli issuer of ETFs and index mutual funds.
The BlueStar Genomic Health Care Index (ticker: BDNANTR) providesexposure to globally listed ‘Genomic Health Care’ companies, the companiesmust derive 50% of revenue or product pipeline from: health care therapiesbased on the targeting or modifying of genetic makeup of cells, technologyplatforms that enable the development of gene editing, or laboratory equipmentor services used to test, code or develop gene editing.
“BlueStar is excited to enable Migdal to offer a unique and cutting-edgehealth care product to its clients. Personalized and precision health care isthe wave of the future in medicine, but the industry is still in its infancy.The BlueStar Genomic Health Care Index provides exposure not only tobiopharmaceutical companies that are primarily offering or developinggene-based therapies but also to the technology and research companies that arecreating platforms for the future development of gene-based therapies,” saidJosh Kaplan, Global Head of Research and Investment Strategy for MVIS.
The BlueStar Genomic Health Care Index (ticker: BDNANTR) is calculated in US Dollars as a totalreturn net index. Detailed information about each index is available on MV Index Solutions website.
Press Release
English
Get the latest news & insights from MarketVector
Get the newsletterRelated:
